Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of SI-B001 plus chemotherapy in advanced EGFR/ALK wild-type non-small cell lung cancer after progression or intolerance to prior PD-1/PD-L1-based therapy
CTR20212811Phase 2Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Jan 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of izalontamab in non-small cell lung cancer (NSCLC), sponsored by Biokin Pharmaceutical. Started Jan 2022; status: active.
02
Drugs
izalontamab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20212811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212811.